semaj83/ctmatch_classification huggingface dataset:
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-90.0,  Osteonecrosis aged between 18-90 years, 2. symptoms of pain and disability in at least one hip joint, or 3. positive MRI findings stage I or II on the ARCO classification  previous hip joint surgery on the affected hip 2. severe pain and disability at rest if treating clinician has recommended surgery 3. radiographic or MRI findings suggestive for stage III and IV on the ARCO classification 4. any iv bisphosphonate within the prior 2 years or any prior use of bisphosphonate preparations, except according to the washout schedule years (if use > 48 weeks) year (if used > 8 weeks but < 48 weeks) months (if used > 2 weeks but < 8 weeks) months (if used < 2 weeks) 5. active primary hyperparathyroidism 6. hypothyroidism, not appropriately controlled with long-term thyroxine therapy 7. history of iritis or uveitis, except due to trauma, and resolved for > 2 years prior to study 8. self-reported history of diabetic nephropathy or retinopathy (if diabetic, Hb A1c > 10%) 9. urine dipstick greater than or equal to 2+ protein at screening 10. AST or ALT greater than twice the upper limit of normal and/or alkaline phosphatase greater than twice the upper limit of normal 11. serum calcium > 2.75 mmol/L (11.0 mg/dL) or < 2.00 mmol/L (8.0 mg/dL) 12. serum 25-hydroxyvitamin D concentrations < 15 ng/L m) baseline renal insufficiency (calculated creatinine clearance less than 40 mL/min and serum creatinine greater than 175 mol/L) at V1 13. a history of invasive malignancy of any organ system, treated or untreated, in the past five years; excluding, basal cell or squamous cell carcinoma of the skin, colonic polyps with non-invasive malignancy which have been removed, ductal carcinoma in-situ (DCIS), and carcinoma in-situ (CIS) of the uterine cervix 14. any candidate patient with severe dental problems or current dental infections and/or any candidate patient with recent or impending dental surgery within three months of dosing 15. women of childbearing potential not using the contraception method(s) specified in this study (specify), as well as women who are breastfeeding
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-99.0,  HIV Infections 18 years old or older. 2. Documented HIV-1 infection, with or without antiretroviral treatment. 3. Presence of WHO osteoporosis defined as t-score under -2.5 in lumbar, hip and/or trochanter (DEXA in the last 6 months is needed). 4. Willing to follow the study protocol. 5. Informed Consent signature  In women, pregnancy or breastfeeding. 2. Other possible causes of secondary osteoporosis. 3. Creatinine over 2.3 mg/mL. 4. Glomerular filter less than 50 mL/min (estimated through MDRD). 5. Treatment for Osteoporosis in the last 4 months
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Bone Neoplasm Patients with primary or recurrent benign bone tumor or tumor-like condition that requires operative treatment by means of tumor evacuation and defect filling Pathological fractures of patients in Stratum I are treated by means of conservative treatment for three months before tumor surgery  History of acute or chronic local infection History of malignancy (excluding carcinoma basocellular) within past 5 years A history of local radiotherapy A known metabolic skeletal disease (such as osteoporosis, Paget's disease or osteomalacia) Medication affecting bone turnover (oral bisphosphonates, PTH, sodium fluoride, strontium ranelate, calcitonin, testosterone, systemic cortico or anabolic steroids) Any plans to use phenol or other chemical/thermal method of local tumor control Pregnancy Any other condition that in the judgment of the investigator, would prohibit the subject from participating in the study or may hinder the collection of data and interpretation of the results
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Metastatic Colorectal Cancer Liver Metastases Hepatic Lesions Histologically or cytologically confirmed carcinoma of the colon and/or rectum with evidence of liver metastases (new confirmation of metastatic disease is required in case the time interval from last histological diagnosis to enrolment exceeds 3 years) Patient with wild type (WT) KRAS tumor status Patient whose liver metastases are considered to be non resectable with curative intent in medico-surgical staff meeting. In particular patients with at least one of the following which prevent complete local treatment of liver metastasis with surgery alone or surgery plus radiofrequency ablation because less than 30% estimated residual liver after resection disease in contact with liver main vessels documented progressive disease on imaging documents or doubling of serum levels of carcino-embryonic antigen (CEA) or CA19.9 over the past 90 days or less Patient with up to three resectable extrahepatic nodules of <= 10 mm One, two or three prior chemotherapy lines for colorectal cancer Written informed consent Age >=18 years  Patient whose primary tumor or metastasis displays mutation of K-Ras (codon 12 and/or 13) Unresectable extrahepatic diseases More than three resectable extrahepatic nodules Size of extra hepatic nodules > 1 cm Prior HAI of the 3 drugs More than 2 prior surgical attempts for metastatic disease Prior radiotherapy for metastatic disease Known documented intolerance or hypersensitivity to any of the drugs used Sensory neuropathy grade 3 (National Cancer Institute-Common Terminology for Adverse Events -NCI-CTCAE, Version 3.0) Past or current history (within the last 2 years prior to treatment start) of malignancy other than colorectal cancer (patients with curatively treated basal and squamous cell carcinoma of the skin or in situ carcinoma of the cervix are eligible)
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-999.0,  Healthy Volunteer Fatigue Depression To be included, participants must meet the following Healthy, 18 years of age or older Speak and understand the English language  Participants with any one of the following will be excluded Inability to provide informed consent for the study Are unwilling or unable to cooperate with the study procedures or travel to NIH for the procedures Have a confirmed medical condition causing clinically significant fatigue symptom (e.g. congestive heart failure, cancer actively receiving therapy, sleep disorders) Currently taking medications that cause fatigue (e.g. diuretics, beta blockers, narcotics) Working late evening and night shifts within the past month Have severe psychiatric conditions (e.g. major depressive disorder, bipolar disorder, anxiety disorder, schizophrenia, drug and/or addiction abuse or dependence) Report consuming more than 300mg of caffeine containing beverages (approximately 4 cups of coffee or 8 cups of soda or tea) or food (approximately 1 lb of chocolate) within 24 hours Reports consuming more than 2 servings of alcohol containing beverages every day and with detectable blood alcohol content (BAC) using breath analyzer (greater than 1 mg/dL of BAC) Pregnant or lactating women
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 5.0-12.0,  Hypophosphatasia Written informed consent from parent or legal guardian prior to participation 2. Boys >/= 5 and < 12 years of age and girls >/= 5 and < 10 years of age with open growth plates at time of enrollment 3. Documented history of HPP, as evidenced by: 1. Presence of HPP-related rickets on skeletal radiographs 2. Serum alkaline phosphatase (ALP) below age-adjusted normal range 3. Plasma PLP at least twice the upper limit of normal (>/=220 nM) 4. Ambulatory without the use of assistive devices 5. Ability of patient and parent/guardian to comply with study requirements  Serum calcium or phosphorus below age-adjusted normal range 2. History of sensitivity to any study drug constituent 3. Medical condition, serious intercurrent illness, or other extenuating circumstance that, in the opinion of the investigator, may significantly interfere with study compliance, including all prescribed evaluations and follow-up activities 4. Treatment with an investigational drug within 1 month before start of study drug 5. Current enrollment in any other study involving an investigational new drug, device, or treatment for HPP (eg, bone marrow transplantation) 6. Current evidence of a treatable form of rickets 7. Prior treatment with bisphosphonates 8. Bone fracture or orthopedic surgery within the past 12 months 9. Major congenital abnormality other than those associated with HPP
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 6.0-999.0,  Hereditary Angioedema To be eligible for this protocol, subjects must: 1. Be ≥6 years of age and ≥25 kg body weight. 2. Have a confirmed diagnosis of HAE with a documented history of swelling of the face, extremities, gastrointestinal tract, genitalia, or larynx and a history of at least one of the following C1 INH gene mutation C4 level below the lower limit of the reference range C1 INH antigen level below the lower limit of the reference range Functional C1 INH level below the lower limit of the reference range Family history of HAE (i.e., grandparent, parent, sibling) 3. Have a history of >1.0 HAE attack per month (average) of any severity during the 3 consecutive months prior to screening while receiving the recommended dosing of 1000 Units every 3 to 4 days via intravenous injection. 4. If an adult, be informed of the nature of the study and provide written informed consent before any study-specific procedures are performed. OR 5. If a child, have a parent/legal guardian who is willing and able to provide written informed consent for the child to participate in the study (with assent from the child when appropriate)  To be eligible for this protocol, subjects must not: 1. Have, as determined by the investigator and/or the sponsor's medical monitor, any surgical or medical condition that could interfere with the administration of study drug or interpretation of study results. 2. Have a history of abnormal blood clotting or other coagulopathy. 3. Be taking prescription anticoagulant medication. 4. Have a history of allergic reaction to or other blood products. 5. Have participated in any other investigational drug study within the past 30 days (other than protocols). 6. Have received any blood products (other than within 60 days prior to screening. 7. Have any of the following laboratory values at screening Hemoglobin <8 g/dL White blood cell count <2 x 10^9/L or >20 x 10^9/L Platelet count <50 x 10^9/L or >400 x 10^9/L Serum aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) >2.0 x the upper limit of normal Blood urea nitrogen and/or creatinine >2.0 x the upper limit of normal 8. Be pregnant or breastfeeding
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 15.0-999.0,  Sinusitis Pain when bending forward, headache, pain in the teeth, purulent nasal secretion, "double worsening" and white blood cell count (WBC) Patients eligible for the study had to meet one of the first three (pain when bending forward, headache, pain in the teeth) and all of the other indicators (purulent nasal secretion, double worsening, a left handed displacement of lymphocytes and a right handed displacement of granulocytes on the WBC as indication of bacterial infection) Subjects over 15 years of age were included  Subjects with any kind of antibiotic or allergic treatment within the last three weeks Antibiotic intolerance Pregnant women
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 7.0-999.0,  Hashimoto's Disease Graves' Disease Clinical diagnosis of abnormal thyroid function (hypo or hyperthyroidism) due to autoimmune thyroid disease  Lack of documentation of abnormal thyroid function or clear evidence of autoimmune etiology
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 18.0-120.0,  Breast Cancer Osteoporosis Patient must be eligible and enrolled in the TEXT-2 trial prior to enrolling in TEXT-Bone Serial bone marrow density (BMD) measurements must be taken within the same institution Hormone receptor positive See Disease Characteristics Premenopausal No bone fracture in the past 6 months that, in the investigator's judgement, could be related to bone fragility No clinical or biochemical malabsorption syndrome, known vitamin D deficiency, active hyper or hypoparathyroidism, or Paget's disease No uncontrolled thyroid disease, Cushing disease, or other pituitary diseases No other bone disease (including osteomalacia or osteogenesis imperfecta) PRIOR
Patient description: The patient is a 60 year old man complaining of frequent headaches, generalized bone pain and difficulty chewing that started 6 years ago and is worsening. Examination shows bilateral swellings around the molars. The swellings have increased since his last examination. Several extraoral lesions are detected in the head and face. The swellings are non-tender and attached to the underlying bone. Further evaluation shows increased uptake of radioactive substance as well as an increase in urinary pyridinoline. His serum alkaline phosphatase is 300 IU/L (the normal range is 44- 147 IU/L). His family history is only significant for hypertension in his mother and DM type 2 in his father. The diagnosis of Paget's Disease of Bone was confirmed and Bisphosphonate will be started as first-line therapy.

Clinical trial eligibility criteria: eligible ages (years): 0.0-1.0,  Osteogenesis Imperfecta Children, male or female 2 weeks to < 12 months of age, at least at 38 weeks gestational age Any child with phenotypic OI type II, III or IV Any child classified as OI type I, V-VIII that has had at least two or more previous fractures of long bone, or vertebral compression fractures, and a low bone mineral density No previous treatment with bisphosphonates Negative urine protein as measured by dipstick. One repeat assessment of the urine protein will be allowed  Blood oxygen saturation of less than 90% in room air Serum creatinine level greater than 56 µmol/L Any clinically significant clinical laboratory abnormalities at screening Treatment with any investigational drug within the past 30 days Patients who are unlikely to be able to complete the study or comply with the visit schedule Any disease or planned therapy which will interfere with the procedures or data collection of this trial